311 related articles for article (PubMed ID: 12901026)
1. Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
Ito MK
Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S15-21; quiz S25. PubMed ID: 12901026
[TBL] [Abstract][Full Text] [Related]
2. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
5. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
6. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
8. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
9. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
12. Extended-release niacin for modifying the lipoprotein profile.
Guyton JR
Expert Opin Pharmacother; 2004 Jun; 5(6):1385-98. PubMed ID: 15163282
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
14. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
15. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins.
Gaw A
Cardiovasc Drugs Ther; 2003 Jan; 17(1):53-62. PubMed ID: 12843687
[TBL] [Abstract][Full Text] [Related]
16. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Duvall WL; Blazing MA; Saxena S; Guyton JR
J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for combined dyslipidemia.
Xydakis AM; Ballantyne CM
Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
[TBL] [Abstract][Full Text] [Related]
18. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
[TBL] [Abstract][Full Text] [Related]
19. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
[TBL] [Abstract][Full Text] [Related]
20. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
